PMC:7205724 / 607-1761 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"50","span":{"begin":720,"end":723},"obj":"Gene"},{"id":"51","span":{"begin":903,"end":906},"obj":"Gene"},{"id":"52","span":{"begin":960,"end":963},"obj":"Gene"},{"id":"53","span":{"begin":4,"end":21},"obj":"Species"},{"id":"54","span":{"begin":23,"end":32},"obj":"Species"},{"id":"55","span":{"begin":86,"end":92},"obj":"Species"},{"id":"56","span":{"begin":177,"end":185},"obj":"Species"},{"id":"57","span":{"begin":243,"end":252},"obj":"Species"},{"id":"58","span":{"begin":284,"end":292},"obj":"Species"},{"id":"59","span":{"begin":389,"end":396},"obj":"Species"},{"id":"60","span":{"begin":836,"end":844},"obj":"Species"},{"id":"61","span":{"begin":941,"end":949},"obj":"Species"},{"id":"62","span":{"begin":1004,"end":1013},"obj":"Species"},{"id":"63","span":{"begin":1065,"end":1074},"obj":"Species"},{"id":"64","span":{"begin":860,"end":871},"obj":"Chemical"},{"id":"65","span":{"begin":58,"end":71},"obj":"Disease"},{"id":"66","span":{"begin":73,"end":81},"obj":"Disease"},{"id":"67","span":{"begin":155,"end":163},"obj":"Disease"},{"id":"68","span":{"begin":201,"end":209},"obj":"Disease"},{"id":"69","span":{"begin":305,"end":313},"obj":"Disease"},{"id":"70","span":{"begin":422,"end":430},"obj":"Disease"},{"id":"71","span":{"begin":454,"end":466},"obj":"Disease"},{"id":"72","span":{"begin":544,"end":552},"obj":"Disease"},{"id":"73","span":{"begin":660,"end":668},"obj":"Disease"},{"id":"74","span":{"begin":677,"end":682},"obj":"Disease"},{"id":"75","span":{"begin":759,"end":767},"obj":"Disease"},{"id":"76","span":{"begin":850,"end":858},"obj":"Disease"},{"id":"77","span":{"begin":1137,"end":1145},"obj":"Disease"}],"attributes":[{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Gene:3569"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Gene:3569"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Gene:3569"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:2697049"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:2697049"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:9606"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:9606"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"Tax:2697049"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"Tax:9606"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"Tax:9606"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:9606"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:9606"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:2697049"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:2697049"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:C502936"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D034062"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:C000657245"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:C000657245"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:C000657245"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:C000657245"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:C000657245"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:D007249"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:C000657245"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:C000657245"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"MESH:D003643"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:C000657245"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"MESH:C000657245"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":165,"end":171},"obj":"Body_part"},{"id":"T3","span":{"begin":711,"end":719},"obj":"Body_part"},{"id":"T4","span":{"begin":747,"end":755},"obj":"Body_part"},{"id":"T5","span":{"begin":886,"end":894},"obj":"Body_part"},{"id":"T6","span":{"begin":1014,"end":1018},"obj":"Body_part"},{"id":"T7","span":{"begin":1089,"end":1102},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma9825"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":1089,"end":1102},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":23,"end":27},"obj":"Disease"},{"id":"T7","span":{"begin":73,"end":81},"obj":"Disease"},{"id":"T8","span":{"begin":155,"end":163},"obj":"Disease"},{"id":"T9","span":{"begin":201,"end":209},"obj":"Disease"},{"id":"T10","span":{"begin":243,"end":247},"obj":"Disease"},{"id":"T11","span":{"begin":305,"end":313},"obj":"Disease"},{"id":"T12","span":{"begin":422,"end":430},"obj":"Disease"},{"id":"T13","span":{"begin":454,"end":466},"obj":"Disease"},{"id":"T14","span":{"begin":544,"end":552},"obj":"Disease"},{"id":"T15","span":{"begin":660,"end":668},"obj":"Disease"},{"id":"T16","span":{"begin":759,"end":767},"obj":"Disease"},{"id":"T17","span":{"begin":850,"end":858},"obj":"Disease"},{"id":"T18","span":{"begin":1004,"end":1008},"obj":"Disease"},{"id":"T19","span":{"begin":1065,"end":1069},"obj":"Disease"},{"id":"T20","span":{"begin":1137,"end":1145},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":44,"end":45},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":86,"end":92},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T3","span":{"begin":165,"end":171},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T4","span":{"begin":253,"end":256},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T5","span":{"begin":873,"end":874},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T6","span":{"begin":1014,"end":1018},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T7","span":{"begin":1089,"end":1102},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":358,"end":373},"obj":"Chemical"},{"id":"T7","span":{"begin":497,"end":512},"obj":"Chemical"},{"id":"T8","span":{"begin":633,"end":648},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T3","span":{"begin":807,"end":817},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A3","pred":"meddra_id","subj":"T3","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062178"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T2","span":{"begin":64,"end":71},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"},{"id":"T3","span":{"begin":1014,"end":1018},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T5","span":{"begin":358,"end":373},"obj":"Chemical"},{"id":"T6","span":{"begin":497,"end":512},"obj":"Chemical"},{"id":"T7","span":{"begin":633,"end":648},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T6","span":{"begin":23,"end":32},"obj":"Species"},{"id":"T7","span":{"begin":73,"end":81},"obj":"Species"},{"id":"T8","span":{"begin":86,"end":92},"obj":"Species"},{"id":"T9","span":{"begin":155,"end":163},"obj":"Species"},{"id":"T10","span":{"begin":201,"end":209},"obj":"Species"},{"id":"T11","span":{"begin":243,"end":252},"obj":"Species"},{"id":"T12","span":{"begin":305,"end":313},"obj":"Species"},{"id":"T13","span":{"begin":422,"end":430},"obj":"Species"},{"id":"T14","span":{"begin":544,"end":552},"obj":"Species"},{"id":"T15","span":{"begin":660,"end":668},"obj":"Species"},{"id":"T16","span":{"begin":759,"end":767},"obj":"Species"},{"id":"T17","span":{"begin":850,"end":858},"obj":"Species"},{"id":"T18","span":{"begin":1004,"end":1013},"obj":"Species"},{"id":"T19","span":{"begin":1065,"end":1074},"obj":"Species"},{"id":"T20","span":{"begin":1137,"end":1145},"obj":"Species"}],"attributes":[{"id":"A14","pred":"ncbi_taxonomy_id","subj":"T14","obj":"NCBItxid:2697049"},{"id":"A13","pred":"ncbi_taxonomy_id","subj":"T13","obj":"NCBItxid:2697049"},{"id":"A11","pred":"ncbi_taxonomy_id","subj":"T11","obj":"NCBItxid:2697049"},{"id":"A18","pred":"ncbi_taxonomy_id","subj":"T18","obj":"NCBItxid:2697049"},{"id":"A9","pred":"ncbi_taxonomy_id","subj":"T9","obj":"NCBItxid:2697049"},{"id":"A7","pred":"ncbi_taxonomy_id","subj":"T7","obj":"NCBItxid:2697049"},{"id":"A17","pred":"ncbi_taxonomy_id","subj":"T17","obj":"NCBItxid:2697049"},{"id":"A8","pred":"ncbi_taxonomy_id","subj":"T8","obj":"NCBItxid:9605"},{"id":"A15","pred":"ncbi_taxonomy_id","subj":"T15","obj":"NCBItxid:2697049"},{"id":"A6","pred":"ncbi_taxonomy_id","subj":"T6","obj":"NCBItxid:2697049"},{"id":"A10","pred":"ncbi_taxonomy_id","subj":"T10","obj":"NCBItxid:2697049"},{"id":"A20","pred":"ncbi_taxonomy_id","subj":"T20","obj":"NCBItxid:2697049"},{"id":"A19","pred":"ncbi_taxonomy_id","subj":"T19","obj":"NCBItxid:2697049"},{"id":"A16","pred":"ncbi_taxonomy_id","subj":"T16","obj":"NCBItxid:2697049"},{"id":"A12","pred":"ncbi_taxonomy_id","subj":"T12","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":93},"obj":"Sentence"},{"id":"T12","span":{"begin":94,"end":164},"obj":"Sentence"},{"id":"T13","span":{"begin":165,"end":314},"obj":"Sentence"},{"id":"T14","span":{"begin":315,"end":406},"obj":"Sentence"},{"id":"T15","span":{"begin":407,"end":467},"obj":"Sentence"},{"id":"T16","span":{"begin":468,"end":553},"obj":"Sentence"},{"id":"T17","span":{"begin":554,"end":683},"obj":"Sentence"},{"id":"T18","span":{"begin":684,"end":859},"obj":"Sentence"},{"id":"T19","span":{"begin":860,"end":971},"obj":"Sentence"},{"id":"T20","span":{"begin":972,"end":1154},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T1","span":{"begin":1089,"end":1102},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"53","span":{"begin":4,"end":21},"obj":"Species"},{"id":"54","span":{"begin":23,"end":32},"obj":"Species"},{"id":"65","span":{"begin":58,"end":71},"obj":"Disease"},{"id":"66","span":{"begin":73,"end":81},"obj":"Disease"},{"id":"55","span":{"begin":86,"end":92},"obj":"Species"},{"id":"67","span":{"begin":155,"end":163},"obj":"Disease"},{"id":"56","span":{"begin":177,"end":185},"obj":"Species"},{"id":"68","span":{"begin":201,"end":209},"obj":"Disease"},{"id":"57","span":{"begin":243,"end":252},"obj":"Species"},{"id":"58","span":{"begin":284,"end":292},"obj":"Species"},{"id":"69","span":{"begin":305,"end":313},"obj":"Disease"},{"id":"59","span":{"begin":389,"end":396},"obj":"Species"},{"id":"70","span":{"begin":422,"end":430},"obj":"Disease"},{"id":"71","span":{"begin":454,"end":466},"obj":"Disease"},{"id":"72","span":{"begin":544,"end":552},"obj":"Disease"},{"id":"73","span":{"begin":660,"end":668},"obj":"Disease"},{"id":"74","span":{"begin":677,"end":682},"obj":"Disease"},{"id":"50","span":{"begin":720,"end":723},"obj":"Gene"},{"id":"75","span":{"begin":759,"end":767},"obj":"Disease"},{"id":"60","span":{"begin":836,"end":844},"obj":"Species"},{"id":"76","span":{"begin":850,"end":858},"obj":"Disease"},{"id":"64","span":{"begin":860,"end":871},"obj":"Chemical"},{"id":"51","span":{"begin":903,"end":906},"obj":"Gene"},{"id":"61","span":{"begin":941,"end":949},"obj":"Species"},{"id":"52","span":{"begin":960,"end":963},"obj":"Gene"},{"id":"62","span":{"begin":1004,"end":1013},"obj":"Species"},{"id":"63","span":{"begin":1065,"end":1074},"obj":"Species"},{"id":"77","span":{"begin":1137,"end":1145},"obj":"Disease"}],"attributes":[{"id":"A75","pred":"pubann:denotes","subj":"75","obj":"MESH:C000657245"},{"id":"A56","pred":"pubann:denotes","subj":"56","obj":"Tax:9606"},{"id":"A64","pred":"pubann:denotes","subj":"64","obj":"MESH:C502936"},{"id":"A66","pred":"pubann:denotes","subj":"66","obj":"MESH:C000657245"},{"id":"A77","pred":"pubann:denotes","subj":"77","obj":"MESH:C000657245"},{"id":"A70","pred":"pubann:denotes","subj":"70","obj":"MESH:C000657245"},{"id":"A52","pred":"pubann:denotes","subj":"52","obj":"Gene:3569"},{"id":"A71","pred":"pubann:denotes","subj":"71","obj":"MESH:D007249"},{"id":"A54","pred":"pubann:denotes","subj":"54","obj":"Tax:2697049"},{"id":"A67","pred":"pubann:denotes","subj":"67","obj":"MESH:C000657245"},{"id":"A50","pred":"pubann:denotes","subj":"50","obj":"Gene:3569"},{"id":"A58","pred":"pubann:denotes","subj":"58","obj":"Tax:9606"},{"id":"A53","pred":"pubann:denotes","subj":"53","obj":"Tax:2697049"},{"id":"A68","pred":"pubann:denotes","subj":"68","obj":"MESH:C000657245"},{"id":"A69","pred":"pubann:denotes","subj":"69","obj":"MESH:C000657245"},{"id":"A51","pred":"pubann:denotes","subj":"51","obj":"Gene:3569"},{"id":"A57","pred":"pubann:denotes","subj":"57","obj":"Tax:2697049"},{"id":"A74","pred":"pubann:denotes","subj":"74","obj":"MESH:D003643"},{"id":"A65","pred":"pubann:denotes","subj":"65","obj":"MESH:D034062"},{"id":"A60","pred":"pubann:denotes","subj":"60","obj":"Tax:9606"},{"id":"A76","pred":"pubann:denotes","subj":"76","obj":"MESH:C000657245"},{"id":"A72","pred":"pubann:denotes","subj":"72","obj":"MESH:C000657245"},{"id":"A62","pred":"pubann:denotes","subj":"62","obj":"Tax:2697049"},{"id":"A63","pred":"pubann:denotes","subj":"63","obj":"Tax:2697049"},{"id":"A55","pred":"pubann:denotes","subj":"55","obj":"Tax:9606"},{"id":"A73","pred":"pubann:denotes","subj":"73","obj":"MESH:C000657245"},{"id":"A59","pred":"pubann:denotes","subj":"59","obj":"Tax:9606"},{"id":"A61","pred":"pubann:denotes","subj":"61","obj":"Tax:9606"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T133","span":{"begin":720,"end":723},"obj":"Protein"},{"id":"T177","span":{"begin":903,"end":906},"obj":"Protein"},{"id":"T221","span":{"begin":960,"end":963},"obj":"Protein"}],"attributes":[{"id":"A221","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A222","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A223","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A224","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A225","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A226","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A227","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A228","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A229","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A230","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A231","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A232","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A233","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A234","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A235","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A236","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A237","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A238","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A239","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A240","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A241","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A242","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A243","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A244","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A245","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A246","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A247","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A248","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A249","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A250","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A251","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A252","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A253","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A254","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A255","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A256","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A257","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A258","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A259","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A260","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A261","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A262","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A263","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A264","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/A0S0B0"},{"id":"A177","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A178","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A179","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A180","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A181","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A182","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A183","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A184","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A185","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A186","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A187","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A188","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A189","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A190","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A191","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A192","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A193","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A194","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A195","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A196","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A197","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A198","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A199","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A200","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A201","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A202","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A203","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A204","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A205","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A206","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A207","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A208","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A209","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A210","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A211","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A212","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A213","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A214","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A215","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A216","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A217","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A218","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A219","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A220","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/A0S0B0"},{"id":"A133","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A134","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A135","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A136","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A137","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A138","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A139","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A140","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A141","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A142","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A143","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A144","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A145","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A146","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A147","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A148","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A149","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A150","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A151","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A152","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A153","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A154","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A155","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A156","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A157","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A158","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A159","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A160","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A161","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A162","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A163","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A164","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A165","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A166","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A167","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A168","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A169","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A170","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A171","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A172","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A173","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A174","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A175","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A176","pred":"uniprot_id","subj":"T133","obj":"https://www.uniprot.org/uniprot/A0S0B0"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T92","span":{"begin":0,"end":3},"obj":"DT"},{"id":"T93","span":{"begin":4,"end":9},"obj":"JJ"},{"id":"T94","span":{"begin":10,"end":21},"obj":"NN"},{"id":"T95","span":{"begin":21,"end":22},"obj":"-COMMA-"},{"id":"T96","span":{"begin":23,"end":32},"obj":"NN"},{"id":"T97","span":{"begin":32,"end":33},"obj":"-COMMA-"},{"id":"T98","span":{"begin":34,"end":37},"obj":"MD"},{"id":"T99","span":{"begin":38,"end":43},"obj":"VB"},{"id":"T100","span":{"begin":44,"end":45},"obj":"DT"},{"id":"T101","span":{"begin":46,"end":57},"obj":"RB"},{"id":"T102","span":{"begin":58,"end":63},"obj":"JJ"},{"id":"T103","span":{"begin":64,"end":71},"obj":"NN"},{"id":"T104","span":{"begin":71,"end":72},"obj":"-COMMA-"},{"id":"T105","span":{"begin":73,"end":81},"obj":"NN"},{"id":"T106","span":{"begin":81,"end":82},"obj":"-COMMA-"},{"id":"T107","span":{"begin":83,"end":85},"obj":"IN"},{"id":"T108","span":{"begin":86,"end":92},"obj":"NNS"},{"id":"T109","span":{"begin":94,"end":98},"obj":"RB"},{"id":"T110","span":{"begin":98,"end":99},"obj":"-COMMA-"},{"id":"T111","span":{"begin":100,"end":102},"obj":"PRP"},{"id":"T112","span":{"begin":103,"end":107},"obj":"MD"},{"id":"T113","span":{"begin":108,"end":115},"obj":"VB"},{"id":"T114","span":{"begin":116,"end":118},"obj":"DT"},{"id":"T115","span":{"begin":119,"end":127},"obj":"NN"},{"id":"T116","span":{"begin":128,"end":130},"obj":"IN"},{"id":"T117","span":{"begin":131,"end":142},"obj":"JJ"},{"id":"T118","span":{"begin":143,"end":150},"obj":"NNS"},{"id":"T119","span":{"begin":151,"end":154},"obj":"IN"},{"id":"T120","span":{"begin":155,"end":163},"obj":"NN"},{"id":"T121","span":{"begin":165,"end":171},"obj":"NN"},{"id":"T122","span":{"begin":172,"end":176},"obj":"IN"},{"id":"T123","span":{"begin":177,"end":185},"obj":"NNS"},{"id":"T124","span":{"begin":186,"end":195},"obj":"VBN"},{"id":"T125","span":{"begin":196,"end":200},"obj":"IN"},{"id":"T126","span":{"begin":201,"end":209},"obj":"NN"},{"id":"T127","span":{"begin":210,"end":214},"obj":"WDT"},{"id":"T128","span":{"begin":215,"end":223},"obj":"VBZ"},{"id":"T129","span":{"begin":224,"end":234},"obj":"NNS"},{"id":"T130","span":{"begin":235,"end":242},"obj":"IN"},{"id":"T131","span":{"begin":243,"end":252},"obj":"NN"},{"id":"T132","span":{"begin":253,"end":256},"obj":"VBZ"},{"id":"T133","span":{"begin":257,"end":262},"obj":"VBN"},{"id":"T134","span":{"begin":263,"end":272},"obj":"JJ"},{"id":"T135","span":{"begin":273,"end":280},"obj":"NNS"},{"id":"T136","span":{"begin":281,"end":283},"obj":"IN"},{"id":"T137","span":{"begin":284,"end":292},"obj":"NNS"},{"id":"T138","span":{"begin":293,"end":297},"obj":"IN"},{"id":"T139","span":{"begin":298,"end":304},"obj":"JJ"},{"id":"T140","span":{"begin":305,"end":313},"obj":"NN"},{"id":"T141","span":{"begin":315,"end":319},"obj":"RB"},{"id":"T142","span":{"begin":319,"end":320},"obj":"-COMMA-"},{"id":"T143","span":{"begin":321,"end":325},"obj":"NNP"},{"id":"T144","span":{"begin":325,"end":326},"obj":"-COMMA-"},{"id":"T145","span":{"begin":327,"end":335},"obj":"VBN"},{"id":"T146","span":{"begin":336,"end":340},"obj":"IN"},{"id":"T147","span":{"begin":341,"end":354},"obj":"NN"},{"id":"T148","span":{"begin":355,"end":357},"obj":"IN"},{"id":"T149","span":{"begin":358,"end":373},"obj":"NNS"},{"id":"T150","span":{"begin":373,"end":374},"obj":"-COMMA-"},{"id":"T151","span":{"begin":375,"end":380},"obj":"MD"},{"id":"T152","span":{"begin":381,"end":388},"obj":"VB"},{"id":"T153","span":{"begin":389,"end":396},"obj":"NN"},{"id":"T154","span":{"begin":397,"end":405},"obj":"NNS"},{"id":"T155","span":{"begin":407,"end":415},"obj":"NN"},{"id":"T156","span":{"begin":416,"end":421},"obj":"VBZ"},{"id":"T157","span":{"begin":422,"end":430},"obj":"NN"},{"id":"T158","span":{"begin":431,"end":433},"obj":"TO"},{"id":"T159","span":{"begin":434,"end":442},"obj":"JJ"},{"id":"T160","span":{"begin":443,"end":450},"obj":"NNS"},{"id":"T161","span":{"begin":451,"end":453},"obj":"IN"},{"id":"T162","span":{"begin":454,"end":466},"obj":"NN"},{"id":"T163","span":{"begin":468,"end":475},"obj":"NNS"},{"id":"T164","span":{"begin":476,"end":480},"obj":"VBP"},{"id":"T165","span":{"begin":481,"end":485},"obj":"IN"},{"id":"T166","span":{"begin":486,"end":489},"obj":"DT"},{"id":"T167","span":{"begin":490,"end":493},"obj":"NN"},{"id":"T168","span":{"begin":494,"end":496},"obj":"IN"},{"id":"T169","span":{"begin":497,"end":512},"obj":"NNS"},{"id":"T170","span":{"begin":513,"end":518},"obj":"MD"},{"id":"T171","span":{"begin":519,"end":529},"obj":"VB"},{"id":"T172","span":{"begin":530,"end":538},"obj":"NN"},{"id":"T173","span":{"begin":539,"end":543},"obj":"IN"},{"id":"T174","span":{"begin":544,"end":552},"obj":"NN"},{"id":"T175","span":{"begin":554,"end":559},"obj":"EX"},{"id":"T176","span":{"begin":560,"end":563},"obj":"VBP"},{"id":"T177","span":{"begin":563,"end":564},"obj":"-COMMA-"},{"id":"T178","span":{"begin":565,"end":572},"obj":"RB"},{"id":"T179","span":{"begin":572,"end":573},"obj":"-COMMA-"},{"id":"T180","span":{"begin":574,"end":576},"obj":"DT"},{"id":"T181","span":{"begin":577,"end":587},"obj":"JJ"},{"id":"T182","span":{"begin":588,"end":596},"obj":"JJ"},{"id":"T183","span":{"begin":597,"end":603},"obj":"NNS"},{"id":"T184","span":{"begin":604,"end":608},"obj":"WDT"},{"id":"T185","span":{"begin":609,"end":613},"obj":"VBP"},{"id":"T186","span":{"begin":614,"end":621},"obj":"IN"},{"id":"T187","span":{"begin":622,"end":625},"obj":"DT"},{"id":"T188","span":{"begin":626,"end":629},"obj":"NN"},{"id":"T189","span":{"begin":630,"end":632},"obj":"IN"},{"id":"T190","span":{"begin":633,"end":648},"obj":"NNS"},{"id":"T191","span":{"begin":649,"end":652},"obj":"MD"},{"id":"T192","span":{"begin":653,"end":659},"obj":"VB"},{"id":"T193","span":{"begin":660,"end":676},"obj":"JJ"},{"id":"T194","span":{"begin":677,"end":682},"obj":"NN"},{"id":"T195","span":{"begin":684,"end":688},"obj":"RB"},{"id":"T196","span":{"begin":688,"end":689},"obj":"-COMMA-"},{"id":"T197","span":{"begin":690,"end":693},"obj":"DT"},{"id":"T198","span":{"begin":694,"end":710},"obj":"JJ"},{"id":"T199","span":{"begin":711,"end":719},"obj":"NN"},{"id":"T200","span":{"begin":720,"end":723},"obj":"NN"},{"id":"T201","span":{"begin":724,"end":726},"obj":"VBZ"},{"id":"T202","span":{"begin":727,"end":730},"obj":"DT"},{"id":"T203","span":{"begin":731,"end":746},"obj":"JJ"},{"id":"T204","span":{"begin":747,"end":755},"obj":"NN"},{"id":"T205","span":{"begin":756,"end":758},"obj":"IN"},{"id":"T206","span":{"begin":759,"end":767},"obj":"NN"},{"id":"T207","span":{"begin":768,"end":778},"obj":"VBD"},{"id":"T208","span":{"begin":779,"end":783},"obj":"IN"},{"id":"T209","span":{"begin":784,"end":792},"obj":"NN"},{"id":"T210","span":{"begin":792,"end":793},"obj":"-COMMA-"},{"id":"T211","span":{"begin":794,"end":805},"obj":"NN"},{"id":"T212","span":{"begin":805,"end":806},"obj":"-COMMA-"},{"id":"T213","span":{"begin":807,"end":812},"obj":"JJ"},{"id":"T214","span":{"begin":813,"end":817},"obj":"NN"},{"id":"T215","span":{"begin":817,"end":818},"obj":"-COMMA-"},{"id":"T216","span":{"begin":819,"end":822},"obj":"CC"},{"id":"T217","span":{"begin":823,"end":832},"obj":"NN"},{"id":"T218","span":{"begin":833,"end":835},"obj":"IN"},{"id":"T219","span":{"begin":836,"end":844},"obj":"NNS"},{"id":"T220","span":{"begin":845,"end":849},"obj":"IN"},{"id":"T221","span":{"begin":850,"end":858},"obj":"NN"},{"id":"T222","span":{"begin":860,"end":871},"obj":"NNP"},{"id":"T223","span":{"begin":871,"end":872},"obj":"-COMMA-"},{"id":"T224","span":{"begin":873,"end":874},"obj":"DT"},{"id":"T225","span":{"begin":875,"end":885},"obj":"JJ"},{"id":"T226","span":{"begin":886,"end":894},"obj":"NN"},{"id":"T227","span":{"begin":895,"end":902},"obj":"IN"},{"id":"T228","span":{"begin":903,"end":906},"obj":"NN"},{"id":"T229","span":{"begin":906,"end":907},"obj":"-COMMA-"},{"id":"T230","span":{"begin":908,"end":913},"obj":"MD"},{"id":"T231","span":{"begin":914,"end":920},"obj":"VB"},{"id":"T232","span":{"begin":921,"end":929},"obj":"JJ"},{"id":"T233","span":{"begin":930,"end":937},"obj":"NN"},{"id":"T234","span":{"begin":938,"end":940},"obj":"IN"},{"id":"T235","span":{"begin":941,"end":949},"obj":"NNS"},{"id":"T236","span":{"begin":950,"end":954},"obj":"IN"},{"id":"T237","span":{"begin":955,"end":959},"obj":"JJ"},{"id":"T238","span":{"begin":960,"end":963},"obj":"NN"},{"id":"T239","span":{"begin":964,"end":970},"obj":"NNS"},{"id":"T240","span":{"begin":972,"end":981},"obj":"JJ"},{"id":"T241","span":{"begin":982,"end":990},"obj":"NNS"},{"id":"T242","span":{"begin":991,"end":995},"obj":"IN"},{"id":"T243","span":{"begin":996,"end":1003},"obj":"NN"},{"id":"T244","span":{"begin":1004,"end":1013},"obj":"NN"},{"id":"T245","span":{"begin":1014,"end":1018},"obj":"NN"},{"id":"T246","span":{"begin":1019,"end":1024},"obj":"NN"},{"id":"T247","span":{"begin":1025,"end":1028},"obj":"CC"},{"id":"T248","span":{"begin":1029,"end":1037},"obj":"JJ"},{"id":"T249","span":{"begin":1038,"end":1053},"obj":"NNS"},{"id":"T250","span":{"begin":1054,"end":1058},"obj":"WDT"},{"id":"T251","span":{"begin":1059,"end":1064},"obj":"VBP"},{"id":"T252","span":{"begin":1065,"end":1074},"obj":"NN"},{"id":"T253","span":{"begin":1075,"end":1077},"obj":"TO"},{"id":"T254","span":{"begin":1078,"end":1084},"obj":"VB"},{"id":"T255","span":{"begin":1085,"end":1088},"obj":"DT"},{"id":"T256","span":{"begin":1089,"end":1095},"obj":"JJ"},{"id":"T257","span":{"begin":1096,"end":1102},"obj":"NN"},{"id":"T258","span":{"begin":1103,"end":1107},"obj":"VBP"},{"id":"T259","span":{"begin":1108,"end":1111},"obj":"DT"},{"id":"T260","span":{"begin":1112,"end":1121},"obj":"NN"},{"id":"T261","span":{"begin":1122,"end":1124},"obj":"IN"},{"id":"T262","span":{"begin":1125,"end":1132},"obj":"NNS"},{"id":"T263","span":{"begin":1133,"end":1136},"obj":"IN"},{"id":"T264","span":{"begin":1137,"end":1145},"obj":"NN"},{"id":"T265","span":{"begin":1146,"end":1153},"obj":"NN"}],"relations":[{"id":"R245","pred":"arg1Of","subj":"T254","obj":"T253"},{"id":"R246","pred":"arg1Of","subj":"T252","obj":"T254"},{"id":"R248","pred":"arg1Of","subj":"T257","obj":"T255"},{"id":"R249","pred":"arg1Of","subj":"T257","obj":"T256"},{"id":"R250","pred":"arg1Of","subj":"T247","obj":"T258"},{"id":"R251","pred":"arg2Of","subj":"T260","obj":"T258"},{"id":"R252","pred":"arg1Of","subj":"T260","obj":"T259"},{"id":"R253","pred":"arg1Of","subj":"T258","obj":"T261"},{"id":"R85","pred":"arg1Of","subj":"T94","obj":"T92"},{"id":"R86","pred":"arg1Of","subj":"T94","obj":"T93"},{"id":"R87","pred":"arg1Of","subj":"T94","obj":"T95"},{"id":"R88","pred":"arg2Of","subj":"T96","obj":"T95"},{"id":"R89","pred":"arg1Of","subj":"T99","obj":"T97"},{"id":"R90","pred":"arg1Of","subj":"T94","obj":"T98"},{"id":"R91","pred":"arg2Of","subj":"T99","obj":"T98"},{"id":"R92","pred":"arg1Of","subj":"T94","obj":"T99"},{"id":"R93","pred":"arg2Of","subj":"T103","obj":"T99"},{"id":"R94","pred":"arg1Of","subj":"T103","obj":"T100"},{"id":"R95","pred":"arg1Of","subj":"T102","obj":"T101"},{"id":"R96","pred":"arg1Of","subj":"T103","obj":"T102"},{"id":"R97","pred":"arg1Of","subj":"T103","obj":"T104"},{"id":"R98","pred":"arg2Of","subj":"T105","obj":"T104"},{"id":"R99","pred":"arg1Of","subj":"T99","obj":"T106"},{"id":"R100","pred":"arg1Of","subj":"T99","obj":"T107"},{"id":"R101","pred":"arg2Of","subj":"T108","obj":"T107"},{"id":"R102","pred":"arg1Of","subj":"T113","obj":"T109"},{"id":"R103","pred":"arg1Of","subj":"T113","obj":"T110"},{"id":"R104","pred":"arg1Of","subj":"T111","obj":"T112"},{"id":"R105","pred":"arg2Of","subj":"T113","obj":"T112"},{"id":"R106","pred":"arg1Of","subj":"T111","obj":"T113"},{"id":"R107","pred":"arg2Of","subj":"T115","obj":"T113"},{"id":"R108","pred":"arg1Of","subj":"T115","obj":"T114"},{"id":"R109","pred":"arg1Of","subj":"T115","obj":"T116"},{"id":"R110","pred":"arg2Of","subj":"T118","obj":"T116"},{"id":"R111","pred":"arg1Of","subj":"T118","obj":"T117"},{"id":"R112","pred":"arg1Of","subj":"T115","obj":"T119"},{"id":"R113","pred":"arg2Of","subj":"T120","obj":"T119"},{"id":"R114","pred":"arg1Of","subj":"T121","obj":"T122"},{"id":"R115","pred":"arg2Of","subj":"T123","obj":"T122"},{"id":"R116","pred":"arg2Of","subj":"T123","obj":"T124"},{"id":"R117","pred":"arg1Of","subj":"T124","obj":"T125"},{"id":"R118","pred":"arg2Of","subj":"T126","obj":"T125"},{"id":"R119","pred":"arg1Of","subj":"T126","obj":"T127"},{"id":"R120","pred":"arg1Of","subj":"T126","obj":"T128"},{"id":"R121","pred":"arg2Of","subj":"T129","obj":"T128"},{"id":"R122","pred":"arg1Of","subj":"T129","obj":"T130"},{"id":"R123","pred":"arg2Of","subj":"T131","obj":"T130"},{"id":"R124","pred":"arg1Of","subj":"T121","obj":"T132"},{"id":"R125","pred":"arg2Of","subj":"T133","obj":"T132"},{"id":"R126","pred":"arg1Of","subj":"T121","obj":"T133"},{"id":"R127","pred":"arg2Of","subj":"T135","obj":"T133"},{"id":"R128","pred":"arg1Of","subj":"T135","obj":"T134"},{"id":"R129","pred":"arg1Of","subj":"T133","obj":"T136"},{"id":"R130","pred":"arg2Of","subj":"T137","obj":"T136"},{"id":"R131","pred":"arg1Of","subj":"T137","obj":"T138"},{"id":"R132","pred":"arg2Of","subj":"T140","obj":"T138"},{"id":"R133","pred":"arg1Of","subj":"T140","obj":"T139"},{"id":"R134","pred":"arg1Of","subj":"T152","obj":"T141"},{"id":"R135","pred":"arg1Of","subj":"T152","obj":"T142"},{"id":"R136","pred":"arg1Of","subj":"T143","obj":"T144"},{"id":"R137","pred":"arg2Of","subj":"T143","obj":"T145"},{"id":"R138","pred":"arg1Of","subj":"T145","obj":"T146"},{"id":"R139","pred":"arg2Of","subj":"T147","obj":"T146"},{"id":"R140","pred":"arg1Of","subj":"T147","obj":"T148"},{"id":"R141","pred":"arg2Of","subj":"T149","obj":"T148"},{"id":"R142","pred":"arg1Of","subj":"T152","obj":"T150"},{"id":"R143","pred":"arg1Of","subj":"T143","obj":"T151"},{"id":"R144","pred":"arg2Of","subj":"T152","obj":"T151"},{"id":"R145","pred":"arg1Of","subj":"T143","obj":"T152"},{"id":"R146","pred":"arg2Of","subj":"T154","obj":"T152"},{"id":"R147","pred":"arg1Of","subj":"T154","obj":"T153"},{"id":"R148","pred":"arg1Of","subj":"T155","obj":"T156"},{"id":"R149","pred":"arg2Of","subj":"T157","obj":"T156"},{"id":"R150","pred":"arg1Of","subj":"T156","obj":"T158"},{"id":"R151","pred":"arg2Of","subj":"T160","obj":"T158"},{"id":"R152","pred":"arg1Of","subj":"T160","obj":"T159"},{"id":"R153","pred":"arg1Of","subj":"T160","obj":"T161"},{"id":"R154","pred":"arg2Of","subj":"T162","obj":"T161"},{"id":"R155","pred":"arg1Of","subj":"T163","obj":"T164"},{"id":"R156","pred":"arg2Of","subj":"T171","obj":"T164"},{"id":"R157","pred":"arg1Of","subj":"T171","obj":"T165"},{"id":"R158","pred":"arg1Of","subj":"T167","obj":"T166"},{"id":"R159","pred":"arg1Of","subj":"T167","obj":"T168"},{"id":"R160","pred":"arg2Of","subj":"T169","obj":"T168"},{"id":"R161","pred":"arg1Of","subj":"T167","obj":"T170"},{"id":"R162","pred":"arg2Of","subj":"T171","obj":"T170"},{"id":"R163","pred":"arg1Of","subj":"T167","obj":"T171"},{"id":"R164","pred":"arg2Of","subj":"T172","obj":"T171"},{"id":"R165","pred":"arg1Of","subj":"T172","obj":"T173"},{"id":"R166","pred":"arg2Of","subj":"T174","obj":"T173"},{"id":"R167","pred":"arg1Of","subj":"T175","obj":"T176"},{"id":"R168","pred":"arg2Of","subj":"T183","obj":"T176"},{"id":"R169","pred":"arg1Of","subj":"T176","obj":"T177"},{"id":"R170","pred":"arg1Of","subj":"T176","obj":"T178"},{"id":"R171","pred":"arg1Of","subj":"T176","obj":"T179"},{"id":"R172","pred":"arg1Of","subj":"T183","obj":"T180"},{"id":"R173","pred":"arg1Of","subj":"T182","obj":"T181"},{"id":"R174","pred":"arg1Of","subj":"T183","obj":"T182"},{"id":"R175","pred":"arg1Of","subj":"T183","obj":"T184"},{"id":"R176","pred":"arg1Of","subj":"T183","obj":"T185"},{"id":"R177","pred":"arg2Of","subj":"T192","obj":"T185"},{"id":"R178","pred":"arg1Of","subj":"T192","obj":"T186"},{"id":"R179","pred":"arg1Of","subj":"T188","obj":"T187"},{"id":"R180","pred":"arg1Of","subj":"T188","obj":"T189"},{"id":"R181","pred":"arg2Of","subj":"T190","obj":"T189"},{"id":"R182","pred":"arg1Of","subj":"T188","obj":"T191"},{"id":"R183","pred":"arg2Of","subj":"T192","obj":"T191"},{"id":"R184","pred":"arg1Of","subj":"T188","obj":"T192"},{"id":"R185","pred":"arg2Of","subj":"T194","obj":"T192"},{"id":"R186","pred":"arg1Of","subj":"T194","obj":"T193"},{"id":"R187","pred":"arg1Of","subj":"T201","obj":"T195"},{"id":"R188","pred":"arg1Of","subj":"T201","obj":"T196"},{"id":"R189","pred":"arg1Of","subj":"T200","obj":"T197"},{"id":"R190","pred":"arg1Of","subj":"T200","obj":"T198"},{"id":"R191","pred":"arg1Of","subj":"T200","obj":"T199"},{"id":"R192","pred":"arg1Of","subj":"T200","obj":"T201"},{"id":"R193","pred":"arg2Of","subj":"T204","obj":"T201"},{"id":"R194","pred":"arg1Of","subj":"T204","obj":"T202"},{"id":"R195","pred":"arg1Of","subj":"T204","obj":"T203"},{"id":"R196","pred":"arg1Of","subj":"T204","obj":"T205"},{"id":"R197","pred":"arg2Of","subj":"T216","obj":"T205"},{"id":"R198","pred":"arg2Of","subj":"T206","obj":"T207"},{"id":"R199","pred":"arg1Of","subj":"T207","obj":"T208"},{"id":"R200","pred":"arg2Of","subj":"T209","obj":"T208"},{"id":"R201","pred":"arg1Of","subj":"T209","obj":"T210"},{"id":"R202","pred":"arg2Of","subj":"T211","obj":"T210"},{"id":"R203","pred":"arg1Of","subj":"T206","obj":"T212"},{"id":"R204","pred":"arg2Of","subj":"T214","obj":"T212"},{"id":"R205","pred":"arg1Of","subj":"T214","obj":"T213"},{"id":"R206","pred":"arg1Of","subj":"T216","obj":"T215"},{"id":"R207","pred":"arg1Of","subj":"T212","obj":"T216"},{"id":"R208","pred":"arg2Of","subj":"T217","obj":"T216"},{"id":"R209","pred":"arg1Of","subj":"T217","obj":"T218"},{"id":"R210","pred":"arg2Of","subj":"T219","obj":"T218"},{"id":"R211","pred":"arg1Of","subj":"T219","obj":"T220"},{"id":"R212","pred":"arg2Of","subj":"T221","obj":"T220"},{"id":"R213","pred":"arg1Of","subj":"T222","obj":"T223"},{"id":"R214","pred":"arg2Of","subj":"T226","obj":"T223"},{"id":"R215","pred":"arg1Of","subj":"T226","obj":"T224"},{"id":"R216","pred":"arg1Of","subj":"T226","obj":"T225"},{"id":"R217","pred":"arg1Of","subj":"T226","obj":"T227"},{"id":"R218","pred":"arg2Of","subj":"T228","obj":"T227"},{"id":"R219","pred":"arg1Of","subj":"T231","obj":"T229"},{"id":"R220","pred":"arg1Of","subj":"T222","obj":"T230"},{"id":"R221","pred":"arg2Of","subj":"T231","obj":"T230"},{"id":"R222","pred":"arg1Of","subj":"T222","obj":"T231"},{"id":"R223","pred":"arg2Of","subj":"T233","obj":"T231"},{"id":"R224","pred":"arg1Of","subj":"T233","obj":"T232"},{"id":"R225","pred":"arg1Of","subj":"T231","obj":"T234"},{"id":"R226","pred":"arg2Of","subj":"T235","obj":"T234"},{"id":"R227","pred":"arg1Of","subj":"T235","obj":"T236"},{"id":"R228","pred":"arg2Of","subj":"T239","obj":"T236"},{"id":"R229","pred":"arg1Of","subj":"T239","obj":"T237"},{"id":"R230","pred":"arg1Of","subj":"T239","obj":"T238"},{"id":"R231","pred":"arg1Of","subj":"T241","obj":"T240"},{"id":"R232","pred":"arg1Of","subj":"T241","obj":"T242"},{"id":"R233","pred":"arg2Of","subj":"T247","obj":"T242"},{"id":"R234","pred":"arg3Of","subj":"T258","obj":"T242"},{"id":"R235","pred":"arg1Of","subj":"T246","obj":"T243"},{"id":"R236","pred":"arg1Of","subj":"T246","obj":"T244"},{"id":"R237","pred":"arg1Of","subj":"T246","obj":"T245"},{"id":"R238","pred":"arg1Of","subj":"T246","obj":"T247"},{"id":"R239","pred":"arg2Of","subj":"T249","obj":"T247"},{"id":"R240","pred":"arg1Of","subj":"T249","obj":"T248"},{"id":"R241","pred":"arg1Of","subj":"T249","obj":"T250"},{"id":"R242","pred":"arg1Of","subj":"T249","obj":"T251"},{"id":"R243","pred":"arg2Of","subj":"T252","obj":"T251"},{"id":"R244","pred":"arg3Of","subj":"T254","obj":"T251"},{"id":"R247","pred":"arg2Of","subj":"T257","obj":"T254"},{"id":"R254","pred":"arg2Of","subj":"T262","obj":"T261"},{"id":"R255","pred":"arg1Of","subj":"T262","obj":"T263"},{"id":"R256","pred":"arg2Of","subj":"T265","obj":"T263"},{"id":"R257","pred":"arg1Of","subj":"T265","obj":"T264"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T1","span":{"begin":454,"end":466},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T2","span":{"begin":677,"end":682},"obj":"http://purl.obolibrary.org/obo/GO_0016265"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T2","span":{"begin":165,"end":171},"obj":"Body_part"},{"id":"T3","span":{"begin":711,"end":719},"obj":"Body_part"},{"id":"T4","span":{"begin":747,"end":755},"obj":"Body_part"},{"id":"T5","span":{"begin":886,"end":894},"obj":"Body_part"},{"id":"T6","span":{"begin":1014,"end":1018},"obj":"Body_part"},{"id":"T7","span":{"begin":1089,"end":1102},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma9825"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T6","span":{"begin":23,"end":32},"obj":"Disease"},{"id":"T7","span":{"begin":73,"end":81},"obj":"Disease"},{"id":"T8","span":{"begin":155,"end":163},"obj":"Disease"},{"id":"T9","span":{"begin":201,"end":209},"obj":"Disease"},{"id":"T10","span":{"begin":243,"end":252},"obj":"Disease"},{"id":"T11","span":{"begin":305,"end":313},"obj":"Disease"},{"id":"T12","span":{"begin":422,"end":430},"obj":"Disease"},{"id":"T13","span":{"begin":454,"end":466},"obj":"Disease"},{"id":"T14","span":{"begin":544,"end":552},"obj":"Disease"},{"id":"T15","span":{"begin":660,"end":668},"obj":"Disease"},{"id":"T16","span":{"begin":759,"end":767},"obj":"Disease"},{"id":"T17","span":{"begin":850,"end":858},"obj":"Disease"},{"id":"T18","span":{"begin":1004,"end":1013},"obj":"Disease"},{"id":"T19","span":{"begin":1065,"end":1074},"obj":"Disease"},{"id":"T20","span":{"begin":1137,"end":1145},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T1","span":{"begin":454,"end":466},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":454,"end":466},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":93},"obj":"Sentence"},{"id":"T12","span":{"begin":94,"end":164},"obj":"Sentence"},{"id":"T13","span":{"begin":165,"end":314},"obj":"Sentence"},{"id":"T14","span":{"begin":315,"end":406},"obj":"Sentence"},{"id":"T15","span":{"begin":407,"end":467},"obj":"Sentence"},{"id":"T16","span":{"begin":468,"end":553},"obj":"Sentence"},{"id":"T17","span":{"begin":554,"end":683},"obj":"Sentence"},{"id":"T18","span":{"begin":684,"end":859},"obj":"Sentence"},{"id":"T19","span":{"begin":860,"end":971},"obj":"Sentence"},{"id":"T20","span":{"begin":972,"end":1154},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."}